Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774253 · ClinicalTrials.gov registry record · Phase 2
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
A Phase 2 study, sponsored by Giselle Sholler.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01774253 is a Phase 2 study that was terminated before completion, run by Giselle Sholler. The registered enrollment target is 9 participants.
The verdict
NCT01774253, a Phase 2 study, was terminated before completion, sponsored by Giselle Sholler.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate an investigational drug (Vismodegib) for Pontine Glioma that is growing or has come back (reoccurred). This study will look at the tumors response to the study drug, Vismodegib, and will also look at the safety and tolerability of Vismodegib. Vismodegib has been tested in multiple adult clinical trials and one pediatric trial. Laboratory testing in pontine gliomas suggests that this drug may be effective in treating this disease.
Interventions
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01774253
The ClinicalTrials.gov registry entry for NCT01774253 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vismodegib is the first listed.
NCT01774253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01774253 about?
NCT01774253 is a clinical study titled "Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma". The purpose of this research study is to evaluate an investigational drug (Vismodegib) for Pontine Glioma that is growing or has come back (reoccurred). This study will look at the tumors response to the study drug, Vismodegib, and will also look at the safety and tolerability of Vismodegib. Vismod...
What is the current status of trial NCT01774253?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01774253?
The interventions under investigation include: Vismodegib (DRUG).
Who is sponsoring clinical trial NCT01774253?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.